Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. OPFOLDA (miglustat)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

OPFOLDA (miglustat)

Medicine - Posted on Nov 09 2023
Active substance (DCI)
  • miglustat
history (2)
  • 10/18/23

    POMBILITI (cipaglucosidase alfa) / OPFOLDA (miglustat) - late-onset Pompe's disease

    Key points Approval of reimbursement only for the indication for use "POMBILITI (cipaglucosidase alfa) is a long-term enzyme...
    CAV :
    54321
    icône flèche
  • 7/27/23

    POMBILITI (cipaglucosidase alfa) - OPFOLDA (miglustat) en association - Forme tardive maladie de Pompe

    Autorisation d’accès précoce refusée aux spécialités POMBILITI (cipaglucosidase alfa) et OPFOLDA (miglustat) dans l'indicati...
    icône flèche
Technical information
ATC code
  • A16AX06
Manufacturer
AMICUS THERAPEUTICS SAS
Presentation

OPFOLDA 65 mg, gélule
Bouteille (PEHD) – Boite de 4 gélules (CIP : 34009 302 760 7 5)
Bouteille (PEHD) – Boîte de 24 gélules (CIP : 34009 550 963 1 3)

All our publications
    Congenital, genetic and rare diseases Drug therapy Metabolic diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
2pTyS1JRV8Q28MnE